优化抗逆转录病毒依从性评估的交叉生物测量研究。

IF 2.9 3区 医学 Q3 IMMUNOLOGY JAIDS Journal of Acquired Immune Deficiency Syndromes Pub Date : 2024-11-21 DOI:10.1097/QAI.0000000000003570
Aaron S Devanathan, Amanda J Poliseno, Nicole R White, Amanda P Schauer, Craig Sykes, Ann Marie K Weideman, Kayla W Kilpatrick, Michael G Hudgens, Cynthia L Gay, Elias P Rosen, Julie B Dumond, Angela Dm Kashuba, Mackenzie L Cottrell
{"title":"优化抗逆转录病毒依从性评估的交叉生物测量研究。","authors":"Aaron S Devanathan, Amanda J Poliseno, Nicole R White, Amanda P Schauer, Craig Sykes, Ann Marie K Weideman, Kayla W Kilpatrick, Michael G Hudgens, Cynthia L Gay, Elias P Rosen, Julie B Dumond, Angela Dm Kashuba, Mackenzie L Cottrell","doi":"10.1097/QAI.0000000000003570","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Incomplete adherence to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) reduces effectiveness. Adherence biomeasures (i.e. drug concentrations in biological specimen) are more accurate than self-report. TDF/FTC's intracellular active metabolites (tenofovir-diphosphate; TFVdp and FTC-triphosphate; FTCtp) can be quantified in different types of blood samples to estimate adherence. To optimize adherence estimation, we investigated approaches to measure TFVdp and FTCtp in four blood matrices.</p><p><strong>Methods: </strong>Twelve HIV-negative, healthy volunteers were enrolled in a single center, open-label, 3-phase, directly observed therapy study. LC-MS/MS methods quantified TFVdp/FTCtp in dried blood spots, volumetrically accurate microsampling, upper layer packed cells and peripheral blood mononuclear cells (PBMCs). Non-compartmental analysis estimated half-lives and accumulation ratios. Correlations characterized relationships between clinical variables and exposure. Regression models were fit to determine concentrations associated with <4 and ≥4 doses/week; correct classification percentages were determined.</p><p><strong>Results: </strong>Terminal half-life estimates of 3-4 vs 15-22 days distinguished between moderate-term (FTCtp in all samples; TFVdp in PBMCs) versus long-term (TFVdp in red blood cell-containing matrices) measures. Model-derived thresholds accurately categorized <4 and ≥4 doses/week when including both metabolites for 14- and 28-day dosing periods (81-91% and 82-85%, respectively). Within each classification and regression trees analyses containing both moderate- and long-term measures, dried blood spots exhibited highest accuracy to predict stable (74-94%) and changing (42-47%) adherence patterns.</p><p><strong>Conclusion: </strong>We demonstrate higher accuracy of moderate-term biomeasures to classify adherence over a 14-day period compared to long-term biomeasures to classify adherence over a 28-day period. Combined moderate- and long-term biomeasures predicted stable and changing adherence patterns, with dried blood spots exhibiting highest accuracy.</p>","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation.\",\"authors\":\"Aaron S Devanathan, Amanda J Poliseno, Nicole R White, Amanda P Schauer, Craig Sykes, Ann Marie K Weideman, Kayla W Kilpatrick, Michael G Hudgens, Cynthia L Gay, Elias P Rosen, Julie B Dumond, Angela Dm Kashuba, Mackenzie L Cottrell\",\"doi\":\"10.1097/QAI.0000000000003570\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Incomplete adherence to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) reduces effectiveness. Adherence biomeasures (i.e. drug concentrations in biological specimen) are more accurate than self-report. TDF/FTC's intracellular active metabolites (tenofovir-diphosphate; TFVdp and FTC-triphosphate; FTCtp) can be quantified in different types of blood samples to estimate adherence. To optimize adherence estimation, we investigated approaches to measure TFVdp and FTCtp in four blood matrices.</p><p><strong>Methods: </strong>Twelve HIV-negative, healthy volunteers were enrolled in a single center, open-label, 3-phase, directly observed therapy study. LC-MS/MS methods quantified TFVdp/FTCtp in dried blood spots, volumetrically accurate microsampling, upper layer packed cells and peripheral blood mononuclear cells (PBMCs). Non-compartmental analysis estimated half-lives and accumulation ratios. Correlations characterized relationships between clinical variables and exposure. Regression models were fit to determine concentrations associated with <4 and ≥4 doses/week; correct classification percentages were determined.</p><p><strong>Results: </strong>Terminal half-life estimates of 3-4 vs 15-22 days distinguished between moderate-term (FTCtp in all samples; TFVdp in PBMCs) versus long-term (TFVdp in red blood cell-containing matrices) measures. Model-derived thresholds accurately categorized <4 and ≥4 doses/week when including both metabolites for 14- and 28-day dosing periods (81-91% and 82-85%, respectively). Within each classification and regression trees analyses containing both moderate- and long-term measures, dried blood spots exhibited highest accuracy to predict stable (74-94%) and changing (42-47%) adherence patterns.</p><p><strong>Conclusion: </strong>We demonstrate higher accuracy of moderate-term biomeasures to classify adherence over a 14-day period compared to long-term biomeasures to classify adherence over a 28-day period. Combined moderate- and long-term biomeasures predicted stable and changing adherence patterns, with dried blood spots exhibiting highest accuracy.</p>\",\"PeriodicalId\":14588,\"journal\":{\"name\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-11-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/QAI.0000000000003570\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/QAI.0000000000003570","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:不完全坚持每日富马酸替诺福韦二氧吡酯/恩曲他滨(TDF/FTC)会降低疗效。粘附性生物测量(即生物标本中的药物浓度)比自我报告更准确。TDF/FTC细胞内活性代谢物(替诺福韦二磷酸;TFVdp和ftc -三磷酸;FTCtp)可以在不同类型的血液样本中量化,以估计依从性。为了优化依从性评估,我们研究了四种血液基质中TFVdp和FTCtp的测量方法。方法:12名hiv阴性的健康志愿者参加单中心、开放标签、三期、直接观察治疗研究。LC-MS/MS方法定量测定干血斑、体积精确微样、上层填充细胞和外周血单个核细胞(PBMCs)中的TFVdp/FTCtp。非区室分析估计了半衰期和积累比。相关性表征了临床变量与暴露之间的关系。拟合回归模型以确定与以下因素相关的浓度:所有样品中中期(FTCtp)的终末半衰期估计为3-4天和15-22天;PBMCs中的TFVdp)与长期(含红细胞基质中的TFVdp)测量。结论:我们证明,与对28天依从性进行分类的长期生物测量相比,对14天依从性进行分类的中期生物测量具有更高的准确性。结合中度和长期生物测量预测稳定和变化的粘附模式,干燥的血点显示出最高的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
A Cross-Biomeasure Study to Optimize Antiretroviral Adherence Estimation.

Background: Incomplete adherence to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) reduces effectiveness. Adherence biomeasures (i.e. drug concentrations in biological specimen) are more accurate than self-report. TDF/FTC's intracellular active metabolites (tenofovir-diphosphate; TFVdp and FTC-triphosphate; FTCtp) can be quantified in different types of blood samples to estimate adherence. To optimize adherence estimation, we investigated approaches to measure TFVdp and FTCtp in four blood matrices.

Methods: Twelve HIV-negative, healthy volunteers were enrolled in a single center, open-label, 3-phase, directly observed therapy study. LC-MS/MS methods quantified TFVdp/FTCtp in dried blood spots, volumetrically accurate microsampling, upper layer packed cells and peripheral blood mononuclear cells (PBMCs). Non-compartmental analysis estimated half-lives and accumulation ratios. Correlations characterized relationships between clinical variables and exposure. Regression models were fit to determine concentrations associated with <4 and ≥4 doses/week; correct classification percentages were determined.

Results: Terminal half-life estimates of 3-4 vs 15-22 days distinguished between moderate-term (FTCtp in all samples; TFVdp in PBMCs) versus long-term (TFVdp in red blood cell-containing matrices) measures. Model-derived thresholds accurately categorized <4 and ≥4 doses/week when including both metabolites for 14- and 28-day dosing periods (81-91% and 82-85%, respectively). Within each classification and regression trees analyses containing both moderate- and long-term measures, dried blood spots exhibited highest accuracy to predict stable (74-94%) and changing (42-47%) adherence patterns.

Conclusion: We demonstrate higher accuracy of moderate-term biomeasures to classify adherence over a 14-day period compared to long-term biomeasures to classify adherence over a 28-day period. Combined moderate- and long-term biomeasures predicted stable and changing adherence patterns, with dried blood spots exhibiting highest accuracy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.80
自引率
5.60%
发文量
490
审稿时长
3-6 weeks
期刊介绍: JAIDS: Journal of Acquired Immune Deficiency Syndromes​ seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide. JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.
期刊最新文献
Modeling Travel Time to HIV Treatment in Malawi: Identifying Rural-Urban and Wealth Inequities. Trends in the Uptake of Index Testing Among Adolescents in USAID-Supported President's Emergency Plan for AIDS Relief Programs, October 2017-September 2022. Intersecting Structural and Psychosocial Conditions: Investigating Injection Drug Use and HIV Among Transgender Women. Racial and Ethnic Disparities in HIV Diagnosis Rates by Social Determinants of Health at the Census Tract Level Among Adults in the United States and Puerto Rico, 2021. Addressing Methamphetamine Use Is Essential to Stopping HIV Transmission.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1